Humana shares soar as it becomes the biggest beneficiary of the 2027 Medicare star ratings.
路透社2026/10/09 11:12Reuters, October 9 – In pre-market trading on Friday, shares of Humana (stock code: HUM.N) rose by 15%. Analysts said the health insurer is set to be the biggest beneficiary of the new 2027 Medicare Advantage star ratings. Humana stated that, with improvements in healthcare quality and member experience indicators, 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher by 2027, a substantial jump from 20% in 2026 (link). JPMorgan analysts noted that they had previously projected this ratio to be between 60% and 70%. The U.S. Department of Health and Human Services uses a one- to five-star scale to rate Medicare Advantage and prescription drug plans. Higher ratings lead to government bonuses worth billions of dollars and can help attract more members. Analysts noted that Humana’s ratings performance outpaced its larger competitors: JPMorgan expects the proportion of UnitedHealth Group’s (UNH.N) plans rated four stars or higher to decrease from 81% to about 67%, while CVS Health’s (CVS.N) ratio will fall from 84% to about 70%. The U.S. Department of Health and Human Services said Thursday night that, overall, about 71% (link) of Medicare Advantage prescription drug plan enrollees will be in contracts rated four stars or higher in 2027. Evercore ISI analyst Elizabeth Anderson said that Humana had improved in prescription drug plan quality, health plan quality, and readmission rates. She added, “This improvement reflects management’s increased focus on these metrics over the past year.” Health insurers provide Medicare Advantage plans for the government to adults aged 65 and older and people with disabilities.
Reuters, October 9 - In pre-market trading on Friday, shares of Humana (stock code: HUM.N) rose 15%, after analysts said that the health insurer is the biggest beneficiary of the 2027 Medicare Advantage new star rating.
Humana said that as healthcare quality and member experience indicators improve, by 2027, 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher, a significant increase from just 20% in 2026 (link).
Analysts at JPMorgan said they had previously expected this ratio to be 60% to 70%.
The U.S. Department of Health and Human Services uses a one-to-five star scale to rate Medicare Advantage and prescription drug plans. Higher ratings bring government-awarded bonuses that can total tens of billions of dollars, and help boost plan enrollment.
Analysts said Humana’s ratings performance outpaced its larger competitors: JPMorgan expects UnitedHealth Group (UnitedHealth) UNH.N to see its proportion of four-star and above plans drop from 81% to about 67%, while CVS Health CVS.N will see this percentage fall from 84% to about 70%.
The U.S. Department of Health and Human Services said Thursday night that overall, about 71% (link) of Medicare Advantage prescription drug plan members will be signed up to contracts rated four stars or higher in 2027.
Evercore ISI analyst Elizabeth Anderson said that Humana improved in areas such as prescription drug plan quality, health plan quality, and readmission rates.
She said this improvement “reflects the management’s focus over the past year on improving these metrics”.
Health insurers offer Medicare Advantage on behalf of the government for adults aged 65 and older and for people with disabilities.
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Due to possible mistakes with automation or lack of intended context, Reuters does not guarantee the accuracy of automated translation text and provides it solely for reader convenience. Reuters accepts no liability for any damages or losses arising from use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Interpretation - What is the low-frequency spectrum obtained by SpaceX for Starlink Mobile?
Harshita Mary Varghese, Reuters, October 9 - SpaceX SPCX.O has agreed to acquire a portfolio of low-band spectrum licenses covering the entire United States, in a deal reportedly valued at $8 billion. The company is seeking to expand its business beyond satellite internet and become a major competitor in the U.S. mobile market. SpaceX revealed its plans to enter the mobile service sector during its first earnings call in August. This announcement briefly weighed on the company’s stock price, and shares of the three major U.S. wireless carriers—AT&T, T-Mobile, and Verizon—were also affected as investors assessed the potential competitive threat. What is low-band spectrum? Low-band spectrum refers to radio waves that travel further and penetrate buildings better compared to higher frequencies, making them suitable for wide-area mobile network coverage. In contrast, mid-band and high-band spectrums can transmit more data at faster speeds but have a smaller coverage area. SpaceX has agreed to purchase up to 14 MHz of paired 800 MHz low-band spectrum licenses from Grain Management and plans to develop a hybrid architecture for Starlink Mobile, combining terrestrial infrastructure with satellite connectivity. How is the U.S. spectrum licensing system structured? Commercial spectrum is a scarce resource in the U.S., regulated by the Federal Communications Commission (FCC), which typically allocates licenses for specific frequencies and geographic areas via auctions or other authorization processes. License holders must comply with technical rules and deployment requirements, and transfers of licenses usually require regulatory approval before obligations are fulfilled. The spectrum license deal recently struck by SpaceX is pending FCC approval. Which low-band spectrum do the three major carriers hold? AT&T’s low-band spectrum includes the 700 MHz and 850 MHz bands, as well as 600 MHz spectrum licenses acquired this July through the purchase of EchoStar. Verizon holds spectrum in the 700 MHz and 850 MHz bands, while T-Mobile’s low-band holdings include 600 MHz and 700 MHz spectrum. What are the plans for STARLINK MOBILE? The company plans to integrate these spectrum licenses into its next-generation satellite system, while also deploying terrestrial radio equipment and antennas on communication towers and rooftops. The FCC this week approved Starlink Mobile’s application for its second-generation (Gen2) satellite constellation, authorizing SpaceX to launch 15,000 satellites globally optimized for the 2 GHz spectrum.
Japanese Yen: Choppy trade inside defined range – UOB
BUZZ—U.S. Stock Market Update—SpaceX, Humana, Crescent Energy
Query string for tracking individual stock trends: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Briefing": https://refini.tv/3dKUyB8 Reuters, October 9 – On Friday, U.S. stock indices are expected to open higher, boosted by falling oil prices as concerns over Middle East supply ease, although telecom stocks remain under pressure amid worries of increased industry-wide competition following SpaceX's spectrum acquisition. ** T-Mobile US Inc TMUS.O: In Discussion – European telecom stocks fell after SpaceX's spectrum deal nL6N45V0EH ** SpaceX SPCX.O: In Focus – Shares rose after reaching an agreement to acquire a nationwide low-band spectrum portfolio nL4N45V0KP ** Humana Inc HUM.N: In Focus – Shares rose on the back of an upgraded rating for its “Federal Medicare Advantage Plan” [nL4N45V0LU ** Definium Therapeutics Inc DFTX.O: Market Watch – Stock rose after JPMorgan rated its LSD-based therapies as “Overweight” nL4N45V0NH ** UnitedHealth Group Inc UNH.N: Market Update – TD Cowen lowered its price target ahead of UnitedHealth’s Q3 financials nL4N45V0OU ** Newmont Corporation NEM.N: ** Gold Fields Ltd GFI.N: ** Harmony Gold Mining Company HMY.N: ** AngloGold Ashanti AU.N: Market Update – Gold miner stocks rose modestly as gold prices moved up on weaker dollar nL4N45V0PG ** Delta Air Lines DAL.N: Market Flash – Shares dropped after sharply cutting its full-year profit guidance nL4N45V0RA ** Apple AAPL.O: In Focus – Shares fell on reports of iPhone production cuts nL4N45V0SB ** Crescent Energy CRGY.N: Market Update – Shares dropped after it raised $1 billion to acquire Devon Energy nL6N45V0J4 ** Medtronic MDT.N: ** Tandem Diabetes Care Inc TNDM.O: ** PROCEPT BioRobotics Corp PRCT.O: ** Insulet Corporation PODD.O: Market Update – Leerink says industry-wide growth concerns for med-tech may outweigh Q3 results nL4N45V0YE (For the convenience of non-English speakers, Reuters automates translation of its reports into several languages. Because automated translations may contain errors or fail to capture the intended context, Reuters does not guarantee the accuracy of these texts and provides them solely for reader convenience. Reuters assumes no liability for any damages or losses resulting from the use of automated translation features.)
BUZZ - Leerink says concerns over growth in the medical technology sector may overshadow third-quarter performance
October 9 – Leerink Partners stated that, ahead of the third-quarter earnings reports, it remains cautious on the medical technology sector and pointed out that the short-term market environment is “somewhat uncertain.” The firm noted increasing competition in some markets, including the cardiac devices and diabetes care sectors; uncertainty in surgical volumes amid rising costs; weak consumer confidence; and pressure on hospital budgets due to higher interest rates. “We believe that even if third-quarter results are positive, they may be overshadowed by ongoing market concerns about profitability and growth prospects for 2027 and beyond,” the broker said. The firm believes that positive factors for specific companies could help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry during these sector-wide headwinds. The broker said it remains most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O), as a slowdown in adoption and intensifying competition may lead to lowered expectations for 2027. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of automated translation texts, and they are provided merely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
Crypto prices
More
